NIH

Patients treated in intensive care units across the globe enter their medical care with no evidence of cognitive impairment but often leave with deficits similar to those seen in patients with traumatic brain injury (TBI) or mild Alzheimer’s disease (AD) that persist for at least a year, according to a Vanderbilt University Medical Center study published today in the New England Journal of Medicine.

Vanderbilt researchers used existing genome-wide association study datasets to identify gene interactions that contribute to tooth decay.

A panel of metabolites – small molecules that are part of metabolic processes – that are unique to macular degeneration will shed light on the disease and aid diagnosis.

Molecular characterization of pre-cancerous changes in cells lining the stomach could point to lesions with a greater risk of progression to cancer.

The Vanderbilt Vaccine Research Program has received a major contract from the National Institutes of Health to continue its work as one of the nation’s Vaccine and Treatment Evaluation Units.

Vanderbilt’s Vaccine and Treatment Evaluation Unit (VTEU) is one of nine U.S. sites funded by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to test the effectiveness of a vaccine to protect against the H7N9 bird flu that emerged in China this spring.

Vanderbilt investigators used an in vivo screen in zebrafish to identify a potential new anti-cancer drug.